Expansion momentum Sharp Services is actively expanding its European and US footprint, investing over €20 million in European packaging facilities in 2026 and scaling facilities in Belgium, the Netherlands, and Massachusetts. This indicates a growing demand for sterile fill/finish, autoinjectors and assembly services, creating cross-sell opportunities for packaging, serialization, regulatory support, and cold-chain storage solutions.

Leadership tech Appointment of a new Chief Technology Officer in 2026 plus a tech stack spanning AWS, enterprise platforms, and digital transformation signals a strategic push toward digital manufacturing, data-driven operations, and integrated IT/OT solutions. This opens doors for MSP-style partnerships, cloud-based compliance, data integration, and automation services.

Global scale assets With facilities across the US, UK, Belgium, and the Netherlands and 30+ clinical depots worldwide, Sharp Services demonstrates global reach and end-to-end capabilities from development to lifecycle management. This creates opportunities to consolidate supplier ecosystems, provide end-to-end serialization, QP services, and global distribution/IR management for multinational clients.

Clinical to commercial Sharp provides integrated services from R&D through to commercial launch including sterile development, fill/finish, primary/secondary packaging, and clinical IRT. This continuum positions Sharp to cross-sell extended services to pharma/biotech clients moving from clinical to commercial phases, as well as to providers needing end-to-end packaging and regulatory readiness.

Investing in injectables Significant investments in European packaging facilities and syringe blistering suites, plus expansion of related warehousing and cold-chain capabilities, indicate a focus on high-demand injectable products. This presents sales opportunities for advanced packaging lines, stability storage solutions, cold-chain logistics, and tamper-evident serialization for injectable portfolios.